← Back to Screener

CMPX Report

08-04-2026 | Analyze. Execute. Alpha.

Performance Framework

Earning
Sentiment
Estimate
Short interest
Cdrs
Ta analysis (short term)
Ta analysis (long term)
Insiders action
Institutional conviction
Mf

Key Metrics & Valuation

Market Cap 0.70B$
Next Earning Release 2026-05-14 00:00:00 (NA days)
Correlation to Market 87.0%
Technical Trend Trending up
Current Ratio 15.0
Return on Equity -43.6%
PEG Ratio -0.8
EV/EBITDA -13.0
EV/Revenue 0.0
EV/FCF -13.8
Price to Earning Correlation -20.2%
Total R&D (5yr % of Rev) 29554.5%
Institutional Holding 10926.0%

Earnings & Cash Flow

  • This quarter EPS is 18.2% related to same quarter last year.
  • Annual earning is -16.7% compared to last year.
  • Annual average earning surprise in the last 5 years is -9.6%.
  • 1.0 of the last 4 quarters had positive surprise.

EBITDA

  • This quarter EBITDA is 100.0% related to same quarter last year.

Free Cash Flow (FCF)

  • This quarter FCF is -9.5% related to same quarter last year.

Revenue/Income

Revenue

  • This quarter revenue is 0.0% related to same quarter last year.

Net Income

  • This quarter income is -4.5% related to same quarter last year.
  • Income ratio in the last 4 quarters, is trending down .

Sentiment

News Sentiment

  • Short term: 0.0% positive, 0.0% negative.
  • Long term: 37.8% positive, 0.0% negative.

Short Interest

  • Short ratio (Days to cover): 11.7
  • Short as % of float: 20.8%
  • Float share amount is trending down.

Future Estimates

Revenue 0.0%
Net Income 3.6%
EPS 3.3%
Price Target Up Side 102.5%

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Next earning release is on 2026-05-14 00:00:00, in NA days

Technical Analysis

Hourly Momentum

Daily Framework

Weekly Strategic

Interactive Chart

Additional Resources

  • Premium Analysis Locked
  • AI Analyst Reasoning


    Content Locked Premium Analysis Locked (Contact for Access)